Farringdon Capital’s DexCom DXCM Stock Holding History

Farringdon Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,437	Closed	-$844K	–	264
2026 Q1	$844K	Buy	+13,437	New	+$936K	0.18%	155

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Farringdon Capital's DXCM Position: Q2 2026 in Review

Farringdon Capital sold out of DexCom (DXCM) in Q2 2026, closing a stake of 13,437 shares — an estimated $844K sold.

Farringdon Capital first reported a position in DXCM in Q1 2026 and held it in 1 quarter. The position peaked at $844K in Q1 2026. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Farringdon Capital reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
Farringdon Capital sold 13,437 DexCom shares in Q2 2026, an estimated $844K.
Farringdon Capital first reported a position in DexCom in Q1 2026 and held it in 1 quarter.
Farringdon Capital's DexCom position peaked at $844K in Q1 2026.
973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.